

Elena V Poddubskaya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/706508/publications.pdf>

Version: 2024-02-01

33
papers

16,507
citations

567281

15
h-index

454955

30
g-index

33
all docs

33
docs citations

33
times ranked

16314
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1627-1639.	27.0	7,973
2	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 123-135.	27.0	7,261
3	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and Tj ETQq1 1 0.784314 mgST / Over	17.8	4314
4	Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. <i>International Journal of Cancer</i> , 2018, 143, 2053-2064.	5.1	76
5	RNA sequencing for research and diagnostics in clinical oncology. <i>Seminars in Cancer Biology</i> , 2020, 60, 311-323.	9.6	56
6	Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma. <i>Experimental Hematology and Oncology</i> , 2018, 7, 21.	5.0	40
7	Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). <i>Lung Cancer</i> , 2021, 152, 7-14.	2.0	40
8	Acquired resistance to tyrosine kinase inhibitors may be linked with the decreased sensitivity to X-ray irradiation. <i>Oncotarget</i> , 2018, 9, 5111-5124.	1.8	30
9	Oncobox Bioinformatical Platform for Selecting Potentially Effective Combinations of Target Cancer Drugs Using High-Throughput Gene Expression Data. <i>Cancers</i> , 2018, 10, 365.	3.7	27
10	Personalized prescription of imatinib in recurrent granulosa cell tumor of the ovary: case report. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003434.	1.2	27
11	A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8009-8009.	1.6	27
12	Genome-wide methylotyping resolves breast cancer epigenetic heterogeneity and suggests novel therapeutic perspectives. <i>Epigenomics</i> , 2019, 11, 605-617.	2.1	26
13	RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a004945.	1.2	26
14	RNA Sequencing in Comparison to Immunohistochemistry for Measuring Cancer Biomarkers in Breast Cancer and Lung Cancer Specimens. <i>Biomedicines</i> , 2020, 8, 114.	3.2	22
15	Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1580.	4.1	17
16	Transcriptomics-Guided Personalized Prescription of Targeted Therapeutics for Metastatic ALK-Positive Lung Cancer Case Following Recurrence on ALK Inhibitors. <i>Frontiers in Oncology</i> , 2019, 9, 1026.	2.8	15
17	Activation of intracellular signaling pathways as a new type of biomarkers for selection of target anticancer drugs.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23142-e23142.	1.6	14
18	High-Throughput Mutation Data Now Complement Transcriptomic Profiling: Advances in Molecular Pathway Activation Analysis Approach in Cancer Biology. <i>Cancer Informatics</i> , 2019, 18, 117693511983884.	1.9	13

#	ARTICLE	IF	CITATIONS
19	Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, 344-344.	1.6	13
20	Abnormal promoter DNA hypermethylation of the integrin, nidogen, and dystroglycan genes in breast cancer. Scientific Reports, 2021, 11, 2264.	3.3	12
21	Oncobox, gene expression-based second opinion system for predicting response to treatment in advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, e13143-e13143.	1.6	11
22	DNA methylation in the promoter regions of the laminin family genes in normal and breast carcinoma tissues. Molecular Biology, 2015, 49, 598-607.	1.3	9
23	Abnormal Hypermethylation of CpG Dinucleotides in Promoter Regions of Matrix Metalloproteinases Genes in Breast Cancer and its Relation to Epigenomic Subtypes and HER2 Overexpression. Biomedicines, 2020, 8, 116.	3.2	9
24	Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer. Lung Cancer, 2022, 165, 71-81.	2.0	9
25	Diagnostic Value of Combinatorial Markers in Colorectal Carcinoma. Frontiers in Oncology, 2020, 10, 832.	2.8	8
26	Clinical use of RNA sequencing and oncobox analytics to predict personalized targeted therapeutic efficacy.. Journal of Clinical Oncology, 2020, 38, e13676-e13676.	1.6	7
27	RNA Sequencing Data for FFPE Tumor Blocks Can Be Used for Robust Estimation of Tumor Mutation Burden in Individual Biosamples. Frontiers in Oncology, 2021, 11, 732644.	2.8	6
28	Experimental and Meta-Analytic Validation of RNA Sequencing Signatures for Predicting Status of Microsatellite Instability. Frontiers in Molecular Biosciences, 2021, 8, 737821.	3.5	4
29	Features of the management of cancer patients during the COVID-19 pandemic. SeĀenovskij Vestnik, 2020, 11, 62-73.	0.4	2
30	Endocrine adverse events of immune checkpoint inhibitors: results of a single-center study. SeĀenovskij Vestnik, 2019, 10, 4-11.	0.4	1
31	RNA-sequencing and bioinformatic analysis to pre-assess sensitivity to targeted therapeutics in recurrent glioblastoma.. Journal of Clinical Oncology, 2019, 37, e13533-e13533.	1.6	0
32	Molecular pathway activation-based analysis for personalized prescription of tyrosine kinase inhibitors for advanced solid tumor patients.. Journal of Clinical Oncology, 2019, 37, e15636-e15636.	1.6	0
33	Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study.. Journal of Clinical Oncology, 2020, 38, e21542-e21542.	1.6	0